logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5600.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5600.produseast1
Showing 1 - 20 of 936 Items
Showing 1 - 20 of 936 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data

Pelzer PT, Stuck L, Martinez L, Richards AS, Acuña-Villaorduña C,  et al.
2024-12-19 • Lancet Microbe
2024-12-19 • Lancet Microbe

BACKGROUND

Tuberculosis vaccine trials using disease as the primary endpoint are large, time consuming, and expensive. An earlier immunological measure of the p...

Journal Article
|
Pre-Print

Effect of smoking on drug-resistant tuberculosis treatment outcomes and exploring potential pathways: A multicountry cohort study

Romo ML, LaHood A, Stagg HR, Mitnick CD, Trevisi L,  et al.
2025-08-24 • medRxiv
2025-08-24 • medRxiv

People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with tho...

Journal Article
|
Letter

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid

Chavan V, Silsarma A, Mahajan R, Khan S, Singh P,  et al.
2025-02-01 • IJTLD OPEN
2025-02-01 • IJTLD OPEN
Journal Article
|
Review

The effectiveness of isoniazid preventive treatment among contacts of multidrug-resistant tuberculosis: A systematic review and individual-participant meta-analysis

Martinez L, Campbell JI, Linde L, Boulahbal F, Cayla JA,  et al.
2025-09-23 • American Journal of Respiratory and Critical Care Medicine
2025-09-23 • American Journal of Respiratory and Critical Care Medicine

RATIONALE

Recent empirical research suggests isoniazid may lead to a risk reduction ...

Journal Article
|
Research

Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children

Delmas V, Vasiliu A, Tchakounté Youngui B, Ssekyanzi B, Kuate Kuate A,  et al.
2025-06-27 • International Journal of Tuberculosis and Lung Disease
2025-06-27 • International Journal of Tuberculosis and Lung Disease

BACKGROUND

The ‘CaP-TB’ project enhanced paediatric TB care through decentralized services, including screening, specimen collection, chest X-rays and implement...

Journal Article
|
Protocol

Evaluating the diagnostic accuracy of WHO-recommended treatment decision algorithms for childhood tuberculosis using an individual person dataset: a study protocol

Olbrich L, Larsson L, Dodd P, Palmer M, Nguyen MHTN,  et al.
2025-09-17 • BMJ Open
2025-09-17 • BMJ Open

INTRODUCTION

In 2022, the WHO conditionally recommended the use of treatment decision algorithms (TDAs) for treatment decision-making in children <10 years with...

Conference Material
|
Slide Presentation

Implementation of treatment-decision algorithms for children with pulmonary tuberculosis: cross-cutting lessons for operational scale-up

Armour-Marshall J, Scarpa G, Abdullahi MB, Farouk Moussa Mamane O, Fidelle Nyikayo L,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025
Journal Article
|
Research

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A,  et al.
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Journal Article
|
Review

Clinical best practices for caring for people with expanded resistance to newer TB drugs

Nkomo T, Udwadia Z, Vambe D, van Rie A, Thi S,  et al.
2025-06-13 • IJTLD OPEN
2025-06-13 • IJTLD OPEN

BACKGROUND

Strains of Mycobacterium tuberculosis

Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article
|
Commentary

Leveraging nutritional rehabilitation and tuberculosis programmes to tackle tuberculosis and severe acute malnutrition in children

Vonasek BJ, Marcy O, Armour J, Casenghi M, Cazes C,  et al.
2025-03-23 • Lancet Child and Adolescent Health
2025-03-23 • Lancet Child and Adolescent Health

Each day more than 500 children younger than 15 years die from tuberculosis. Considerable progress has been...

Journal Article
|
Research

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W,  et al.
2025-08-22 • Clinical Infectious Diseases
2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

Journal Article
|
Research

Concomitant splenic tuberculosis and Epstein–Barr virus-related T-cell leukemia/lymphoma in a 28-year-old pregnant woman in South Sudan

Wild HB, Aumuller J, Kuei J, Simon M, Palm A,  et al.
2025-06-04 • American Journal of Tropical Medicine and Hygiene
2025-06-04 • American Journal of Tropical Medicine and Hygiene

This case report presents a rare instance of concomitant splenic tuberculosis (TB), Epstein–Barr virus (EBV)-related T-cell leukemia/lymphoma, and malaria in a 28-year-old pregnant wo...

Journal Article
|
Research

Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens

Gotham D, Martin M, Barber MJ, Kazounis E, Batts C,  et al.
2025-04-23 • PLOS Global Public Health
2025-04-23 • PLOS Global Public Health

Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médec...

Journal Article
|
Review

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Kwak N, Kim JY, Han A, Berry C, Beumont M,  et al.
2025-07-17 • European Respiratory Journal
2025-07-17 • European Respiratory Journal

BACKGROUND

The optimal dosing strategy of linezolid for treating multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) remains unclear. We condu...

Journal Article
|
Research

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH,  et al.
2025-07-16 • Lancet Respiratory Medicine
2025-07-16 • Lancet Respiratory Medicine
Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article
|
Review

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J,  et al.
2025-06-06 • Lancet Infectious Diseases
2025-06-06 • Lancet Infectious Diseases
Conference Material
|
Abstract

Implementation of treatment-decision algorithms for children with pulmonary tuberculosis: cross-cutting lessons for operational scale-up

Armour-Marshall J, Scarpa G, Abdullahi MB, Farouk Moussa Mamane O, Fidelle Nyikayo L,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025
Journal Article
|
Research

Centrifuge-free stool processing methods for Xpert MTB/RIF Ultra tuberculosis diagnosis in children in Uganda and Zambia: an observational, prospective, diagnostic accuracy study

Lounnas M, Masama EN, Beneteau S, Kasakwa K, Kaitano R,  et al.
2025-06-01 • Lancet Microbe
2025-06-01 • Lancet Microbe

BACKGROUND

WHO recommends Xpert MTB/RIF Ultra (Ultra) for stool testing for tuberculosis diagnosis in children. Stool processing requires removal of debris and ...